Vivos Therapeutics (VVOS) Free Cash Flow Growth (1y) (2021 - 2026)
Vivos Therapeutics (VVOS) Free Cash Flow Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.07 Bn | 193.46 Bn | 7.27 Bn | 28.87% |
| 2 | Stryker | 127.90 Bn | 124.43 Bn | 4.50 Bn | 14.12% |
| 3 | Medtronic | 118.84 Bn | 109.62 Bn | 6.41 Bn | 0.77% |
| 4 | Boston Scientific | 73.33 Bn | 72.79 Bn | 3.85 Bn | 13.29% |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn | 142.84% |
| 6 | Dexcom | 34.46 Bn | 32.51 Bn | 830.00 Mn | -11.68% |
| 7 | GE HealthCare Technologies | 33.91 Bn | 31.81 Bn | 2.18 Bn | 750.00% |
| 8 | Koninklijke Philips | 26.36 Bn | 23.04 Bn | 4.55 Bn | 0.40% |
| 9 | Steris | 23.12 Bn | 22.64 Bn | 684.20 Mn | -14.34% |
| 10 | Vivos Therapeutics | 4.96 Mn | 3.16 Mn | 2.95 Mn | 15.57% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -53.44% |
| Dec 31, 2025 | -161.34% |
| Sep 30, 2025 | 5.20% |
| Jun 30, 2025 | -35.85% |
| Mar 31, 2025 | -47.06% |
| Dec 31, 2024 | 9.87% |
| Sep 30, 2024 | -83.56% |
| Jun 30, 2024 | 4.52% |
| Mar 31, 2024 | 25.69% |
| Dec 31, 2023 | -7.53% |
| Sep 30, 2023 | 60.18% |
| Jun 30, 2023 | 36.27% |
| Mar 31, 2023 | 42.13% |
| Dec 31, 2022 | 28.66% |
| Sep 30, 2022 | -33.41% |
| Jun 30, 2022 | -2.32% |
| Mar 31, 2022 | -50.42% |
| Dec 31, 2021 | -21.30% |
| Sep 30, 2021 | -548.85% |
| Jun 30, 2021 | -426.92% |